Mumbai, June 25 -- Novo Nordisk, a global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, announced the launch ofWegovy(R)(injectable Semaglutide) in India. Wegovy(R)-a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA)-is thefirst and onlyweight management medication in India indicated for bothlong-term chronic weight management and reduction in risk of major adverse cardiovascular events in people living with the condition.Itis available in five dosing strengths with the convenience of an innovative, easy-to-use pen device.
Wegovy(R) is a prescription-only medication that has the potential to improve the quality of life for millions of Indians living with obesity or overweight. As per the INDIAB study, India has 254 million people with generalized obesity and 351 people with abdominal obesity.
India has the third-highest number of people living with overweight and obesity. Alarmingly, obesity is associated with over 200 diseases, including cardiovascular diseases, certain types of cancer, and type 2 diabetes. Misconceptions about obesity include that it is the result of poor lifestyle choices and a lack of self-discipline. However, obesity is caused by many different factors, including genetics, biology, psychology, society, and the environment we live in. As with other chronic conditions, such as type 2 diabetes or asthma, obesity requireslong-term management with effective treatment solutions.
Clinical studies with Semaglutide 2.4 mg (the active ingredient in Wegovy(R)) demonstrate
20% or more weight reduction in at least 1 in 3 individuals when used along with lifestyle interventions comprising a reduced-calorie diet and increased physical activity.
20% reduction in the risk of major adverse cardiovascular events, like cardiovascular disease-related death, heart attack (myocardial infarction), and stroke, when used on top of standard of care in people with established cardiovascular disease and overweight or obesity.